Cart
sales@molnova.com
EC5026
CAS No. 1809885-32-2
EC5026( BPN-19186 )
Catalog No. M22930 CAS No. 1809885-32-2
EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators. EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids. Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 113 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 332 | In Stock |
|
| 100MG | 494 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEC5026
-
NoteResearch use only, not for human use.
-
Brief DescriptionEC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators. EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids. Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators.
-
DescriptionEC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators. EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids. Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators. sEH inhibitors developed by EicOsis have already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses.
-
In Vitro——
-
In VivoEC5026 (BPN-19186) has already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses.
-
SynonymsBPN-19186
-
PathwayOthers
-
TargetOther Targets
-
RecptorsEH
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1809885-32-2
-
Formula Weight405.39
-
Molecular FormulaC18H23F4N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (616.69 mM)
-
SMILESO=C(NC1CCN(C([C@@H](C)CC)=O)CC1)NC2=CC=C(OC(F)(F)F)C(F)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019.
molnova catalog
related products
-
Ginsenoside Rh3
Ginsenoside Rh3 is a natural product extracted from Ginseng C. A. Mey.Ginsenoside Rh3 has antifungal and antioxidant activities and induces Nrf2 activation in human retinal cells.
-
Isoflurane
Isoflurane is a stable, non-explosive inhalation anesthetic that has been reported to induce caspase-3 activation.
-
SARS-CoV-2-IN-38
SARS-CoV-2-IN-38 is an orally available SARS-CoV-2 inhibitor with potential antiviral activity for the study of SARS viral infections.
